Consolidates ongoing multi-discipline research collaboration
Syngene International, R&D focused contract research organisation, has announced the establishment of an integrated, multi-disciplinary drug discovery and development center for Amgen, in Bengaluru, India. This centre, named Syngene Amgen Research and Development Center (SARC), will be Syngene’s fourth such exclusive R&D centre. Syngene already operates dedicated R&D centres for Bristol-Myers Squibb, Abbott Nutrition and Baxter.
Reportedly, the centre will be staffed by a team of more than 100 Syngene scientists, working in close association with Amgen researchers around the world on the discovery and development of innovative medicines.
In addition to being customised to meet Amgen’s functional requirements, the facility complies with the highest regulatory standards. Claims a company release. Its design includes a range of environmentally-friendly features and flexible layouts, and is configured to minimise solvent and effluent waste with a strong emphasis on laboratory safety and ‘green’ chemistry.
Commenting on the Syngene Amgen Research and Development Center, Jonathan Hunt, Chief Executive Officer, Syngene International, said, “We are delighted to announce the establishment of our dedicated R&D centre for Amgen. Bringing together into one place, the range of activities we conduct on behalf of Amgen indicates the strategic nature of our relationship and also reflects the ability of Syngene’s scientific teams to deliver world-class science towards our partners’ R&D programs in both biotechnology and small molecule medicines.”
Syngene has partnered with Amgen in a variety of discovery and development projects. With the establishment of SARC, this association now extends into a multi-discipline collaboration spanning capabilities in medicinal and process chemistry, biologics, bioprocess, drug metabolism, pharmacokinetics, bioanalytical research, and pharma development.